UNCY Key Statistics, Chart & Performance
The current stock price of UNCY is 6.3 USD. In the past month the price increased by 31.25%. In the past year, price decreased by -8.55%.
UNCY Latest News, Press Relases and Analysis
UNCY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.09 | 402.18B | ||
| AMGN | AMGEN INC | 15.76 | 185.50B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 158.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.89 | 110.80B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.43 | 83.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 872.78 | 58.35B | ||
| INSM | INSMED INC | N/A | 43.23B | ||
| NTRA | NATERA INC | N/A | 32.54B | ||
| BIIB | BIOGEN INC | 10.87 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 22.09B | ||
| INCY | INCYTE CORP | 16.46 | 20.63B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About UNCY
Company Profile
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Company Info
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 22
Phone: 16503840642
UNICYCIVE THERAPEUTICS INC / UNCY FAQ
What does UNCY do?
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Can you provide the latest stock price for UNICYCIVE THERAPEUTICS INC?
The current stock price of UNCY is 6.3 USD. The price increased by 10.14% in the last trading session.
Does UNICYCIVE THERAPEUTICS INC pay dividends?
UNCY does not pay a dividend.
How is the ChartMill rating for UNICYCIVE THERAPEUTICS INC?
UNCY has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of UNICYCIVE THERAPEUTICS INC (UNCY)?
UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.95).
UNCY Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is one of the better performing stocks in the market, outperforming 85.77% of all stocks.
UNCY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
UNCY Financial Highlights
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -3.95. The EPS increased by 61.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -119.44% | ||
| ROE | -509% | ||
| Debt/Equity | 0 |
UNCY Forecast & Estimates
14 analysts have analysed UNCY and the average price target is 54.44 USD. This implies a price increase of 764.17% is expected in the next year compared to the current price of 6.3.